Active Pharmaceutical IngredientIP / EP / USP
Sitagliptin
Description
A DPP-4 inhibitor that boosts insulin release and lowers glucagon by extending the activity of incretin hormones. Works without causing significant hypoglycemia, making it a preferred add-on therapy.
Applications
Formulated into tablets, most commonly as a fixed-dose combination with Metformin for type 2 diabetes management.
Specifications
Therapeutic ClassDiabetes & Metabolic Health
AppearanceWhite To Off-White Powder
Assay / Purity98.0–102.0%
SolubilitySoluble In Water
GradeIP / USP / EP
Manufacturing ComplianceWHO-GMP / EU-GMP / USFDA
Get a tailored quotation for Sitagliptin within 24 business hours.